Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.47 |
| ▸ | CSF1R | P07333 | 3/20 | 0.47 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.41 |
| ▸ | HTR3B | O95264 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.41 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.40 |
| ▸ | RXRG | P48443 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.38 |
| ▸ | CLK1 | P49759 | 1/20 | 0.38 |
| ▸ | CLK2 | P49760 | 1/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.38 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14214689 | 0.85 | EGFR (0.48) | EGFRCSF1RGRM4HTR3EHTR3B | |
| SCHEMBL6493428 | 0.81 | TAAR1 (0.39) | EGFRCSF1RHTR3EHTR3BHTR3A | |
| SCHEMBL4947244 | 0.79 | ALDH1A1 (0.36) | EGFRCSF1RDYRK1ACLK1ALDH1A1 | |
| SCHEMBL4431783 | 0.75 | KDR (0.50) | EGFRCSF1RGRM4HTR3EHTR3B | |
| SCHEMBL6485380 | 0.75 | CAMK2D (0.48) | EGFRMAPTALDH1A1KMT2AFGFR1 | |
| SCHEMBL14214685 | 0.74 | MAPK1 (0.55) | EGFRALDH1A1KMT2AFGFR1KDR | |
| SCHEMBL8344153 | 0.73 | MT-CO2 (0.36) | EGFRCSF1RHTR3EHTR3BHTR3A | |
| SCHEMBL15100699 | 0.71 | RECQL (0.47) | EGFRCSF1RGRM4HTR3EHTR3B | |
| SCHEMBL28322173 | 0.70 | HTR3E (0.52) | EGFRCSF1RGRM4HTR3EHTR3B | |
| SCHEMBL715925 | 0.69 | HSD17B10 (0.39) | DYRK1ACLK1CLK2CLK4DYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1218360-B1 | TRIAZINE KINASE INHIBITORS | AMGEN INC (US) | 2008-05-28 | — | — | EP | disclosed |
| US-7074789-B2 | Kinase inhibitors | AMGEN INC. (US) | 2006-07-11 | — | — | US | disclosed |
| US-6881737-B2 | Substituted triazinyl acrylamide derivatives and methods of use | AMGEN INC. (US) | 2005-04-19 | — | — | US | disclosed |
| US-6864255-B2 | Substituted triazinyl amide derivatives and methods of use | AMGEN INC. (US) | 2005-03-08 | — | — | US | disclosed |
| US-20040116388-A1 | triazine compoound inhibitors of enzymes that catalyze phosphoryl transfer and/or that bind ATP/GTP nucleotides | AMGEN INC. | 2004-06-17 | — | — | US | disclosed |
| EP-1390354-A1 | TRIAZINYL ACRYLAMIDE DERIVATIVES AS KINASE INHIBITORS | Amgen Inc. (US) | 2004-02-25 | — | — | EP | disclosed |
| US-20030139416-A1 | Substituted triazinyl acrylamide derivatives and methods of use | AMGEN INC. | 2003-07-24 | — | — | US | disclosed |
| US-20030087908-A1 | Substituted triazinyl amide derivatives and methods of use | AMGEN INC. | 2003-05-08 | — | — | US | disclosed |
| WO-2002083653-A1 | TRIAZINYL ACRYLAMIDE DERIVATIVES AS KINASE INHIBITORS | AMGEN INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| EP-1218360-A1 | TRIAZINE KINASE INHIBITORS | Amgen Inc., (US) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001025220-A1 | TRIAZINE KINASE INHIBITORS | AMGEN INC. (US) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139416-A1 | Substituted triazinyl acrylamide derivatives and methods of use | PKD1, PKD2, GLS | EGFR 228/4885CSF1R 4638/4885GRM4 3567/4885 |
| US-20030087908-A1 | Substituted triazinyl amide derivatives and methods of use | FLT4, FLT1, VEGFA | EGFR 124/4885CSF1R 1493/4885GRM4 3662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.